Eli Lilly Just Scored Europe's First Weight Loss Pill Approval -- and the Growth Story Keeps Getting Bigger

Eli Lilly's oral weight-loss drug Foundayo received approval in the United Kingdom, marking the first authorization for a GLP-1 oral medication in Europe. The pill competes directly with Novo Nordisk's Wegovy and offers a key convenience advantage: no food-timing restrictions for dosing.

The approval lands as the global obesity drug market is projected to surge from $66 billion in 2025 to between $92 billion and $200 billion by 2027. LLY is positioned to capture share in a market experiencing triple-digit percentage growth potential over a two-year window.

Foundayo's oral formulation eliminates the injection requirement associated with NVO's Wegovy, a differentiation that could drive commercial uptake among needle-averse patients. The U.K. greenlight establishes a regulatory beachhead for LLY's oral GLP-1 strategy in Europe, with potential for additional country approvals to follow.

The drug adds to LLY's existing injectable GLP-1 portfolio and expands the company's addressable market within the obesity category. With the market doubling or potentially tripling by 2027, multiple manufacturers including LLY and NVO are expected to sustain high growth rates.